37 results about "Tos ferina" patented technology

The invention discloses a primer group and a kit for simultaneously detecting nucleic acids of various respiratory pathogens based on twenty-six PCR (Polymerase Chain Reaction). The kit comprises primer pool freeze-dried powder of influenza A virus (FluA), influenza B virus (FluB), respiratory syncytial virus (RSV), human parainfluenza virus (hPIV), mycoplasma pneumoniae (MP), novel coronavirus (SARS-CoV-2), human respiratory adenovirus (HADV), human respiratory nose / enterovirus (HRV / HEV), bordetella pertussis (BP), human coronavirus (HCoV), human bocavirus (HBoV) and chlamydia pneumoniae (CP), PCR (polymerase chain reaction) freeze-dried powder and a buffer solution. According to the kit, primer system optimization is carried out on various pathogens, brand new primers and probe pools are designed, clinical sensitivity and specificity can be achieved, and meanwhile, the kit is matched with a fully-closed full-automatic detection card box integrating sample treatment and amplification and is suitable for rapid detection of respiratory tract pathogens.

The invention pertains to a mutant Bordetella OmpA polypeptide. A Bordetella comprising said mutant polypeptide has a high blebbing phenotype. Hence, the invention further pertains a method for producing OMVs, wherein the method comprises a step of culturing a population of Bordetella bacteria comprising a modified OmpA polypeptide, under conditions conductive for the production of OMVs. In addition, the invention pertains to OMVs produced by a Bordetella comprising a mutant OmpA polypeptide, and the use of such OMVs for the treatment and prevention of a Bordetella infection.

A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

The invention discloses a primer composition for respiratory tract pathogen detection, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at influenza A virus, a primer pair aiming at influenza B virus, a primer pair aiming at bordetella pertussis, a primer pair aiming at adenovirus, a primer pair aiming at respiratory syncytial virus and a primer pair aiming at mycoplasma pneumoniae. The primer composition and related products can be used for simultaneously detecting influenza A viruses (seasonal H1N1, novel influenza A H1N1 viruses (2009), H3N2, H5N1 and H7N9), influenza B viruses (Victoria series and Yamagata series), adenoviruses (group B, group C and group E), respiratory syncytial viruses (subtype A and subtype B), mycoplasma pneumoniae and bordetella pertussis, so that pathogenic pathogens are quickly determined, and the primer composition and related products have important significance on clinical detection.

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.

The invention belongs to the technical field of biology, and relates to an immunocompetence composition and a pertussis vaccine containing the immunocompetence composition. The immunocompetence composition comprises pertussis Bordetella outer membrane vesicles and attenuated pertussis toxins in a weight ratio of (5-50): (5-25). Effective protective immunity can be triggered in the process of preventing pertussis infection, pertussis bacteria in the lung are effectively eradicated, and bacterial colonization in the trachea and the nasal cavity is remarkably reduced.

The invention relates to a Bordetella pertussis genotyping detection kit and a detection method thereof, and the kit comprises a primer pair and a probe aiming at prn genotyping, which are used for carrying out genotyping detection on prn150 / prn1 / 2; the primer pair and the probe aiming at the ptxC gene typing are used for carrying out typing detection on the ptxC4 / ptxC1; the invention relates to a primer pair and a probe aiming at fhaB gene typing, which are used for carrying out typing detection on fhaB1 / fhaB3. The kit disclosed by the invention has the advantages of good sensitivity, high specificity, accuracy, reliability, rapidness, convenience and the like, is suitable for popularization and application in genotyping detection of pertussis bordetella prn150 / prn1, fhaB1 / fhaB3 and ptxC4 / ptxC1 types, and has a wide application prospect.

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 strain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and / or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

The invention discloses a reagent combination and a kit for detecting four respiratory tract pathogens based on qPCR, and belongs to the technical field of microbiological detection. Wherein the four respiratory tract pathogens are respectively human adenovirus, human bocavirus, bordetella pertussis and mycoplasma pneumoniae; the kit also comprises an optimized PCR (Polymerase Chain Reaction) buffer solution, DNA (Deoxyribose Nucleic Acid) polymerase and UDG enzyme. Through screening processes such as specific primer probe design, reagent formula and reaction system optimization, high sensitivity and high specificity are maintained while rapid detection is performed, and missing detection and misjudgment are effectively avoided.

The invention discloses a primer group for MLVA typing of bordetella pertussis and application of the primer group. The primer group for MLVA typing of bordetella pertussis comprises primer sequences of VNTR 1-6, a primer sequence of VNTR 2-6, a primer sequence of VNTR 3-6, a primer sequence of VNTR 4-6 and a primer sequence of VNTR 5-6, through selection of the primer group for pertussis bordetella MLVA typing, the primer group can be directly applied to clinical detection of pertussis positive samples, the sample types can be sputum, throat swab, alveolar lavage fluid and other clinical common sample types, and isolated culture is not needed; besides, the Bordetella pertussis MLVA typing method is short in experimental period, a large amount of sequencing sequence data can be obtained at a time, six groups of primers designed in the invention can be carried out in the same reaction tube, one experiment takes about 24 hours, sequencing results of a plurality of samples can be obtained in combination with an NGS sequencing technology, and the detection efficiency is high.

The invention provides application of a virus detection system in preparation of kits for detecting respiratory pathogens of children, the system comprises a kit for simultaneously detecting influenza A virus, influenza B virus, new coronavirus and bocavirus, and the system comprises a kit for simultaneously detecting influenza A virus, influenza B virus, new coronavirus and enterovirus; the system comprises a kit for simultaneously detecting mycoplasma pneumoniae, pertussis, metapneumovirus and moraxella catarrhalis, the system comprises a kit for simultaneously detecting the rhinovirus, the respiratory syncytial virus, the adenovirus and the mycoplasma pneumoniae; according to the big data analysis result, the typical symptoms of the respiratory tract infection of the children are divided into four types, namely pure continuous hyperpyrexia, pure severe cough, severe cough and hyperpyrexia and pure wheeze, and a plurality of pathogens which are preferentially detected are set for each type of symptoms, so that the detection efficiency can be improved, and the waste of medical resources is avoided.

The invention provides a primer for detecting bordetella pertussis through RPA (recombinase polymerase amplification)-lateral flow immunochromatography. The primer comprises specific primer pairs NAT-F and NAT-R which are designed aiming at transposase genes of a bordetella pertussis IS1663 family, and specific primer pairs NAT-F and NAT-R which are designed aiming at transposase genes of a bordetella pertussis IS1663 family, the invention also provides corresponding probes, which comprise a gold nanoparticle binding probe, a quality control line capture probe and a bordetella pertussis IS1663 capture probe. Meanwhile, the invention further provides application of the primer and the probe in preparation of a pertussis bordetella detection product, a specific detection kit and a specific detection method. According to the invention, the specific primer and probe are designed aiming at the transposase gene of the pertussis bordetella IS110-like element IS1663 family, and the rapid, high-sensitivity and high-specificity detection of pertussis bordetella is realized by fusing the rapid isothermal amplification technology of RPA and the visual detection advantage of lateral flow immunochromatography, no complex instrument or professional operation is needed, and the kit has the advantages of high sensitivity, high specificity, high sensitivity and high specificity. The method is suitable for multi-scene early convenient diagnosis.

The present application belongs to the field of molecular biology detection, and particularly relates to detection of pathogenic bacteria related to respiratory tract infection, and more particularly to detection of Bordetella parapertussis, Bordetella hockingense and Bordetella bronchiseptica. The composition for combined detection provided by the present application mainly utilizes a multiplex fluorescence PCR analysis method, and different pathogenic bacteria are detected by detecting target points on different pathogenic bacteria, so that detection and differentiation of Bordetella parapertussis, Bordetella hockingense and Bordetella bronchiseptica are simultaneously achieved in a single tube reaction system. The composition of the present application has higher sensitivity, reaches 500 copies / mL, has good specificity, and is more accurate in detection.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

The invention discloses an attenuated Bordetella pertussis recombinant strain as well as a construction method and application thereof, and belongs to the technical field of microbial genetic engineering. The invention provides an attenuated Bordetella pertussis recombinant strain, compared with a wild type, the toxicity of the gene detoxification Bordetella pertussis toxin expressed by the recombinant strain is reduced by 106 times, and the gene detoxification Bordetella pertussis toxin modified from the CS strain of Bordetella pertussis is proved to have good protectiveness for the first time in a mouse challenge experiment. The compound can be used for preparing products for treating or / and detecting or / and preventing pertussis diseases, and has a good application prospect.

The invention discloses a method for preparing pertussis component antigens PT and FHA by adopting one-step chromatography, and particularly, the method comprises the following steps: (1) after pertussis thalli are fermented, harvesting supernatant and concentrating to obtain a fermented supernatant concentrated solution; (2) regulating the conductivity and pH value of the fermentation supernatant concentrated solution, and then performing chromatographic purification by adopting a multi-mode weak cation exchange medium, wherein the chromatographic purification comprises the steps of eluting by adopting a first eluent to obtain FHA and eluting by adopting a second eluent to obtain PT; wherein the conductivity of the adjusted fermented supernatant concentrate in the step (2) is less than or equal to 10mS / cm, and the pH value is 6-7.5; the first eluent is a phosphate buffer solution with the pH value of 6-7 and containing 0.12 M-0. 2M of sodium chloride, and the second eluent is a buffer solution with the pH value of 8.5-9.6 and containing 0M of sodium chloride.

The present invention discloses a nucleic acid detection kit for simultaneously detecting 9 respiratory pathogens based on a common qPCR detection platform, comprising the following non-mixing: reaction solution A, reaction solution B, and reaction solution C. Reaction solution A includes forward and reverse primers and fluorescent probes for influenza A virus, influenza B virus, and respiratory syncytial virus; reaction solution B includes forward and reverse primers and fluorescent probes for human parainfluenza virus, Mycoplasma pneumoniae, and the new coronavirus; reaction solution C includes forward and reverse primers and fluorescent probes for human respiratory adenovirus, human respiratory rhinovirus / enterovirus, and Bordetella pertussis. The fluorescent groups of the fluorescent probes used for different pathogens in the same reaction solution are different. The nucleic acid detection kit for simultaneously detecting 9 respiratory pathogens based on a common qPCR detection platform of the present invention has high specificity and high sensitivity, and is suitable for rapid detection of respiratory pathogens.

The invention relates to the technical field of microbial culture and drug sensitivity, in particular to preparation and application of a Bordetella pertussis drug sensitivity detection culture medium. The invention provides a culture medium for performing a drug sensitivity test on clinically separated pertussis bordetella. The culture medium is a carbon-free solid agar culture medium. According to the method, the interference of adsorbing antibiotics by carbon particles is avoided, the small inhibition zone caused by overgrowth of bacteria when an eutrophic plate is used for drug sensitivity can be avoided, the influence on the color of the plate is small after whole blood is replaced with serum, and the color of the plate and the color of a common drug sensitive plate MH culture medium tend to be consistent; the method can be used for detecting the drug sensitivity of the bordetella pertussis.

The invention discloses a composition, a kit and a detection method for detecting pulmonary infection pathogens. The composition comprises at least one of a component A, a component B, a component C and a component D, the component A comprises a primer pair SEQ ID NO: 1-2 and a probe SEQ ID NO: 3; detecting bordetella pertussis by the component A; the component B comprises a primer pair SEQ ID NO: 4-5 and a probe SEQ ID NO: 6; the component B is used for detecting Nocardia; the component C comprises a primer pair SEQ ID NO: 7-8 and a probe SEQ ID NO: 9; detecting cryptococcus neoformans by the component C; the component D comprises a primer pair SEQ ID NO: 10 to 11 and a probe SEQ ID NO: 12; the component D is used for detecting acinetobacter baumannii. The composition for detecting the pulmonary infection pathogens provided by the invention can detect and distinguish at least one of bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, has higher sensitivity, specificity and precision, can accurately and quickly detect bordetella pertussis, nocardia, cryptococcus neoformans and acinetobacter baumannii, and can be used for detecting the pulmonary infection pathogens. The detection efficiency is improved, the detection period is shortened, and detection is convenient.

The present invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) tetanus toxoid, and (c) diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The present invention also provides a composition for use in a method of generating an immune response in a patient, the method comprising the step of administering to the patient the composition of the present invention.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The invention belongs to the technical field of biological medicines and vaccines, and particularly relates to a pertussis Bordetella mRNA (messenger Ribonucleic Acid) vaccine and application thereof. Specifically, the bordetella pertussis mRNA vaccine capable of inducing an organism to generate TH1 immune bias is successfully prepared, three antigens (pertussis toxin, filamentous hemagglutinin and pertussis adhesion) of pertussis are coded by mRNA based on the immune response advantage of the mRNA vaccine, so that the organism can be stimulated to generate good TH1 / TH17 immune response, and the immune response of the organism is enhanced. And thus, colonization and removal of the respiratory tract of the pertussis bacteria are realized, and finally, the protective efficacy of the vaccine is greatly improved, so that the method has good practical application value.

The invention relates to the technical field of biological detection, and discloses a composition for detecting respiratory tract infection pathogens, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting legionella pneumophila, bordetella pertussis, chlamydia pneumoniae, mycoplasma pneumoniae, mycobacterium tuberculosis, aspergillus and cryptococcus neoformans in a sample with high specificity, and has relatively high sensitivity and stability. Compared with traditional detection methods such as pathogen isolated culture and genome sequencing, the efficiency of identifying and jointly detecting multiple respiratory tract pathogens by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

The invention provides a composition, a preparation method, application and a medicine or health food prepared from the composition. The composition is prepared from the following components in parts by weight: 5-20 parts of docosahexaenoic acid, 5-15 parts of eicosapentaenoic acid, 0.5-10 parts of 10-hydroxy-alpha-decenoic acid, 10-30 parts of taurine and 1-20 parts of squalene. According to the present invention, the composition having the immunity regulating effect is provided, and the composition can improve the immune function and can inhibit the growth of bordetella pertussis so as to provide the pertussis prevention and / or treatment effect. The composition disclosed by the invention can be used for preparing medicines for improving the immune function and preventing and / or treating pertussis; meanwhile, the raw materials in the composition are all food additive components meeting the national safety standard, and the composition can be used for preparing health-care food.

The invention discloses a monoclonal antibody aiming at a bordetella pertussis antibody as well as a preparation method and application of the monoclonal antibody. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 of which the sequences are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 of which the sequences are respectively shown as SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The monoclonal antibody can be used as a bordetella pertussis quality control antibody, is applied to the clinical diagnosis of pertussis, and provides reference for the clinical diagnosis of pertussis.

The application discloses a recombinant attenuated Bordetella pertussis strain and a construction method and application thereof, and belongs to the technical field of microbial genetic engineering. The application provides a recombinant attenuated Bordetella pertussis strain, and the gene detoxified pertussis toxin expressed by the recombinant strain is 10 6 times lower in toxicity than the wild type, and the gene detoxified pertussis toxin derived from the CS strain of Bordetella pertussis is proved to have good protectivity in a mouse challenge experiment for the first time, and can be used for preparing products for treating or / and detecting or / and preventing the pertussis disease, and has a good application prospect.

The invention belongs to the technical field of biological detection, and particularly relates to a sample treating fluid for detecting bordetella pertussis, a detection method, a product and application. The sample treatment liquid comprises a lysis working solution (WLB) and a post-treatment diluent (PD), the WLB is composed of choline tartrate, betaine, glycerin, TCEP, IGEPAL CA-630, HEPES and non-enzyme deionized water, and the PD is composed of bovine serum albumin and non-enzyme deionized water. The kit is suitable for common clinical samples such as sputum and nasopharynx swab eluent, bordetella pertussis can be efficiently split, target nucleic acid is fully released, and meanwhile matrix inhibitors such as mucoprotein, heme and protease in the samples are effectively removed. The kit is simple and convenient to operate, free of complex purification steps, high in detection sensitivity, good in reproducibility, high in specificity and free of cross reaction, and provides reliable technical support for early precise diagnosis and epidemic prevention and control of pertussis.

The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.

The present invention relates to vaccines and vaccine compositions, in particular vaccines and vaccine compositions inactivated with antibiotics or antibacterial compounds. In particular, the invention extends to a bacterial vaccine or vaccine composition wherein the bacteria has been inactivated by an antibiotic or an antibacterial compound. The invention further extends to the use of the vaccine and vaccine compositions as a therapeutic or as part of a vaccine in the prevention of infection with a bacterial infection, such as Bordetella pertussis, and the treatment and / or prophylaxis of bacterial diseases, such as pertussis disease (whooping cough).